This prospective, open-label, multicenter, observational study will investigate the effectiveness and safety of MabThera SC (rituximab, subcutaneous) induction therapy in patients with non-Hodgkin's lymphoma, following a first initial treatment of MabThera IV (rituximab, intraveneous). Induction treatment period in the study is estimated to be 8 months.

Inclusion Criteria:

1. Indication according to the Summary of Product Characteristics (SPC) for MabThera SC formulation:

   • As treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy
   • As treatment of patients with CD20 positive diffuse large B cell non-Hodgkin's lymphoma in combination with chemotherapy

2. At least 4 treatment cycles with MabThera is planned

3. Patients >/= 18 years at inclusion

4. Patients written informed consent

5. Treatment decision to prescribe MabThera SC has been taken by the physician prior to recruitment into the study

Exclusion Criteria:

1. Contraindications according to SPC for MabThera SC formulation:

   • Hypersensitivity for the active substance or murine antibodies, hyaluronidase or any other excipients
   • Active and severe infections
   • Patients with severe immunsuppression

2. Patient included in clinical trials with experimental pharmaceuticals

3. Pregnancy

Patients within label indication for MabThera SC and subject for induction therapy with MabThera SC; patients object for maintenance therapy are excluded